In several solid tumors, elevated LAIR2 levels have been associated with improved prognosis and overall survival, suggesting a role for LAIR2 as a potential therapeutic agent that may reduce LAIR1-mediated immune suppression in the tumor microenvironment [166]. The gene discussed is LAIR2; the disease is neoplasm.